IPP Bureau
NPPA has put a cap on the trade margin of 42 select non-scheduled anti-cancer medicines
By IPP Bureau - August 11, 2021
A total of 526 brands has seen a reduction of up to 90 per cent in MRP
SMS Pharmaceuticals revenue grows by 44%; Profit up 235%
By IPP Bureau - August 10, 2021
This robust performance is a testimony of the company's agility, resilience and strong execution capabilities during these difficult times
Bayer strengthens drug discovery platform through acquisition of Vividion Therapeutics
By IPP Bureau - August 10, 2021
Purchase price of US $ 1.5 billion upfront and up to USD 500 million in success-based milestone payments
Merck launches New Pergoveris Pen for fertility treatment in India
By IPP Bureau - August 10, 2021
A globally approved pen filled by mass technology provides a safer self- administration fertility solution
Hinduja Global Solutions sells its healthcare services to Barings for US $ 1.2 billion
By IPP Bureau - August 10, 2021
The healthcare vertical is US-focused, has 35-plus clients and 24,000 employees across 34 locations in five countries
ALS drug RADICAVA holds promise as it completes four years in US
By IPP Bureau - August 10, 2021
Nearly 6,000 patients have been treated with the drug since 2017
INNOVIO QoQ revenues down for the period ended June 30, 2021
By IPP Bureau - August 10, 2021
Company working on COVID vaccine INO 4800
Eagle Pharmaceuticals announces licensing agreement for Landiolol
By IPP Bureau - August 10, 2021
Deal signed with AOP Orphan for US commercial rights
Atara Biotherapeutics, Pascal Touchon, Ameet Mallik, Rafael Holdings
By IPP Bureau - August 10, 2021
A veteran in cell therapy and oncology commercialisation
QIAGEN and OncXerna Therapeutics sign licensing and master companion diagnostic agreements
By IPP Bureau - August 10, 2021
QIAGEN and OncXerna enter into a global master agreement to advance the development of the Xerna TME panel as a potential Next Generation Sequencing (NGS) companion diagnostic for OncXerna’s Navicixizumab
QIAGEN receives U.S. FDA emergency use authorization to analyze over 30 samples per hour
By IPP Bureau - August 10, 2021
QIAreach SARS-CoV-2 antigen test, developed in collaboration with Ellume, is easy to use and provides accurate and objective results in 2 to 15 minutes
Amring Pharmaceuticals launch Isoproterenol Hydrochloride Injection USP
By IPP Bureau - August 10, 2021
The drug is indicated for mild and transient episodes of heart block
Kite and Appia Bio collaborate to research and develop Allogeneic cell therapies for cancer
By IPP Bureau - August 10, 2021
It leverages Kite’s Chimeric Antigen Receptors and Appia Bio’s Allogeneic Cell Technology Platform to Develop Off-the-Shelf Cell Therapies
Pillar Biosciences Receives Premarket Approval from FDA for its oncoReveal Dx Lung and Colon Cancer Assay
By IPP Bureau - August 10, 2021
The product can be used by any lab that conducts NGS testing, making precision medicine accessible to all cancer patients
S-Alpha Therapeutics raises US $ 8.7 million in Series A Funding
By IPP Bureau - August 10, 2021
Founded in 2019, the start-up develops digital therapeutics, a therapeutic intervention from the convergence of biology and information technology
